The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Phase III study of omidubicel in patients with high-risk hematologic malignancies meets primary endpoint
Positive results from a phase III study of omidubicel, a cell therapy product of expanded umbilical cord blood (UCB) cells, (NCT02730299) have been announced.1 The study investigated the safety and efficacy of omidubicel, compared to standard UCB transplant, in patients with high-risk hematological malignancies without a suitable matched donor.2
Key features3,4
Omidubicel
- An advanced cell therapy product consisting of nicotinamide (NAM)-expanded stem cells and differentiated immune cells from UCB
- NAM inhibits differentiation and enhances the functionality of cultured hematopoietic stem and progenitor cells, which substantially increases bone marrow homing and engraftment potential
- Can be cryopreserved and transplanted after myeloablative conditioning as a standalone hematopoietic stem cell graft
- The first bone marrow transplant product to receive the United States Food and Drug Administration (FDA) breakthrough therapy designation and has also received orphan drug designation in the United States and European Union.
- Proven in a phase I/II study, published in the Journal of Clinical Oncology, to induce rapid and durable engraftment, while being well tolerated
Study design2
- Open-label, controlled, multicenter, international, randomized, phase III trial comparing stem cell transplantation with omidubicel vs standard UCB in patients with high-risk hematologic malignancies
- Started in November 2016 and completed in December 2019
- Included 125 patients aged 12–65 years with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, lymphoma, or acute leukemia1
- Primary endpoint: Time to neutrophil engraftment
Top-line results from the study demonstrated that treatment with omidubicel significantly reduced the median time to neutrophil engraftment by 10 days compared to standard UCB transplant (p < 0.001) and was generally well tolerated. Furthermore, a greater percentage of patients achieved successful neutrophil engraftment compared with patients in the comparator group (96% vs 88%, respectively).1
Full efficacy and safety results are expected to be presented later this year, and a biologics license application is due to be submitted to the FDA by the end of the year.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content